The role of the gut microbiome in mood disorders is an emerging, fascinating field in neuroscience and medicine. Numerous studies have shown that the gut microbiota (colonies of both “good” and “bad” bacteria living in [...]
Dr. Lee S. Cohen recently shared news of a new screening application for postpartum depression with ObGyn News
We know that about 15% of women suffer from postpartum depression (PPD). But what is less clear is how to reliably identify women with PPD and to then ensure that they get the support and [...]
We are very pleased to announce the release of the MGH Perinatal Depression Scale available free of charge on the App Store (https://appsto.re/us/-3X4jb.i). The MGHPDS smartphone app includes digital versions of perinatal depression screening tools [...]
It is estimated that suicide accounts for about 10% of all maternal deaths. While we have a fair amount of information to help us predict which women are at risk for depression during pregnancy and [...]
Over the last decade, there has been increased interest around the country in establishing consistent screening for perinatal depression across a range of clinical settings. Approximately 40 states have instituted guidelines and recommendations regarding screening [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547, now called brexanolone, is a new type of antidepressant: a formulation of allopregnanolone, which is [...]
While many women are at risk for postpartum depression, we continue to struggle in providing adequate support and care to women in this setting, especially socioeconomically disadvantaged women. In a randomized clinical trial including [...]
It is clear that screening for perinatal depression substantially improves detection; however, screening alone does not appear to improve rates of treatment or outcomes. What we find is that many, if not most, women with [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. This drug was initially under [...]
